<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752631</url>
  </required_header>
  <id_info>
    <org_study_id>Y(2020)067</org_study_id>
    <nct_id>NCT04752631</nct_id>
  </id_info>
  <brief_title>MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK</brief_title>
  <acronym>ROSE-TNK</acronym>
  <official_title>MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK (ROSE-TNK): a Prospective, Randomized, Blinded Assessment of Outcome and Open Label Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label multicentre trial, evaluating the utility of MRI-guided thrombolysis&#xD;
      for stroke beyond time window by Tenecteplase (TNK-tPA). This exploratory study was to&#xD;
      describe the feasibility and outcome of thrombolytic therapy with TNK-tPA in 4.5-24 hours&#xD;
      after stroke guided by a mismatch between diffusion-weighted imaging and FLAIR in the region&#xD;
      of ischemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with acute stroke with an unknown time of onset, intravenous alteplase guided by&#xD;
      a mismatch between diffusion-weighted imaging and FLAIR in the region of ischemia resulted in&#xD;
      a significantly better functional outcome at 90 days. This trial will enroll acute ischemic&#xD;
      stroke patients within 4.5 to 24 hours of onset. All the patients had an ischemic lesion that&#xD;
      was visible on MRI diffusion-weighted imaging but no parenchymal hyperintensity on&#xD;
      fluid-attenuated inversion recovery (FLAIR), which indicated that the stroke had a ischemic&#xD;
      penumbra. Randomization will be 1:1 to TNK-tPA (experimental) or standard treatment&#xD;
      (control), in compliance with guidelines for acute stroke. Clinical outcome was assessed by&#xD;
      disability on the basis of the modified Rankin scale at 90 days follow-up, which will be&#xD;
      performed by a blinded assessor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The Outcomes will be performed by a blinded assessor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of modified Rankin Scale (mRS) 0-1</measure>
    <time_frame>90 Days</time_frame>
    <description>the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of modified Rankin Scale (mRS) 0-2</measure>
    <time_frame>90 Days</time_frame>
    <description>the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of the modified Rankin Scale (mRS)</measure>
    <time_frame>90 Days</time_frame>
    <description>the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in National Institute of Health stroke scale (NIHSS)</measure>
    <time_frame>24 hours and 1 week</time_frame>
    <description>the minimum and maximum values of NIHSS are 42 and 0, respectively; higher NIHSS mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular events</measure>
    <time_frame>90 Days</time_frame>
    <description>The incidence of stroke and other vascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of death</measure>
    <time_frame>14 days</time_frame>
    <description>death due to any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of symptomatic intracranial hemorrhage (sICH)</measure>
    <time_frame>48 hours</time_frame>
    <description>sICH was defined as 4 or more increase in NIHSS caused by hemorrhage</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of intraparenchymal hemorrhage (PH1 and PH2)</measure>
    <time_frame>48 hours</time_frame>
    <description>Proportion of PH1 and PH2 within 48 hours after the treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>proportion of hemorrhagic transformation</measure>
    <time_frame>7 Days</time_frame>
    <description>Intracranial hemorrhage assessed by MRI/CT</description>
  </other_outcome>
  <other_outcome>
    <measure>any bleeding events</measure>
    <time_frame>7 Days</time_frame>
    <description>proportion of any bleeding events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>TNK-tPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNK-tPA (0.25mg/kg) given as a single bolus over 5-10 seconds immediately upon randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be treated with standard of care in compliance with guidelines for acute stroke</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>The participants received TNK-tPA thrombolytic therapy</description>
    <arm_group_label>TNK-tPA</arm_group_label>
    <other_name>TNK-tPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient age 18-80 years;&#xD;
&#xD;
          2. The time from onset to treatment: 4.5-24 hours;&#xD;
&#xD;
          3. Acute Ischemic stroke confirmed by MRI;&#xD;
&#xD;
          4. NIHSS score ：6-25, or NIHSS score≤ 5 but culprit vessel occlusion or severe stenosis (&#xD;
             ICA, MCA-M1/M2, ACA) on CTA/MRA;&#xD;
&#xD;
          5. Imaging requirements: (1) DWI infarct region: no more than 1/3 of middle cerebral&#xD;
             artery territory or 1/2 of the anterior cerebral artery territory or 1/2 of the&#xD;
             posterior cerebral artery territory; (2) DWI infarct volume &lt;70 ml; (2) presence of&#xD;
             DWI/Flair mismatch: DWI high signal and Flair visually normal;&#xD;
&#xD;
          6. the first onset of ischemic stroke or previous stroke with no obvious sequelae&#xD;
             (mRS≤1);&#xD;
&#xD;
          7. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Planned endovascular treatment;&#xD;
&#xD;
          2. Serious neurological deficits before onset ( mRS ≥ 2);&#xD;
&#xD;
          3. Obvious head injuries or strokes within 3 months;&#xD;
&#xD;
          4. Subarachnoid hemorrhage;&#xD;
&#xD;
          5. History of intracranial hemorrhage;&#xD;
&#xD;
          6. Intracranial tumor, arteriovenous malformation or aneurysm;&#xD;
&#xD;
          7. Intracranial or spinal cord surgery within 3 months;&#xD;
&#xD;
          8. Arterial puncture at a noncompressible site within the previous seven days;&#xD;
&#xD;
          9. Active internal hemorrhage;&#xD;
&#xD;
         10. coagulation abnormalities: platelet count of &lt;100000/mm3 ；&#xD;
&#xD;
         11. Aortic arch dissection；&#xD;
&#xD;
         12. Heparin therapy within 24 hours;&#xD;
&#xD;
         13. Infective endocarditis；&#xD;
&#xD;
         14. Oral warfarin is being taken and INR&gt;1.6 or APTT abnormal；&#xD;
&#xD;
         15. oral anticoagulation therapy；&#xD;
&#xD;
         16. Systolic pressure ≥185 mmHg or diastolic pressure ≥110 mmHg；&#xD;
&#xD;
         17. Blood glucose &lt; 50 mg/dl (2.7mmol/L)；&#xD;
&#xD;
         18. Pregnancy;&#xD;
&#xD;
         19. Neurological deficit after epileptic seizures;&#xD;
&#xD;
         20. Major surgery within 1 month;&#xD;
&#xD;
         21. Gastrointestinal or urinary tract hemorrhage within the previous 30 days;&#xD;
&#xD;
         22. Myocardial infarction within 3 months;&#xD;
&#xD;
         23. allergy to study drugs;&#xD;
&#xD;
         24. Contradictory to MRI examination；&#xD;
&#xD;
         25. MRI image not qualified for evaluation；&#xD;
&#xD;
         26. Other serious illness；&#xD;
&#xD;
         27. Participating in other clinical trials within 3 months;&#xD;
&#xD;
         28. patients not suitable for this clinical studies considered by researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Hui-Sheng, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>General Hospital of Shenyang Military Region</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen Hui-Sheng, Doctor</last_name>
    <phone>86-24-28897511</phone>
    <phone_ext>024-28897512</phone_ext>
    <email>chszh@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang Xin-Hong, Doctor</last_name>
    <phone>86-15309885658</phone>
    <email>450341972@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, General Hospital of Northern Theater Command</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui-Sheng Chen, Ph.D.</last_name>
      <phone>+86 13352452086</phone>
      <email>chszh@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, Cheripelli B, Cho TH, Fazekas F, Fiehler J, Ford I, Galinovic I, Gellissen S, Golsari A, Gregori J, Günther M, Guibernau J, Häusler KG, Hennerici M, Kemmling A, Marstrand J, Modrau B, Neeb L, Perez de la Ossa N, Puig J, Ringleb P, Roy P, Scheel E, Schonewille W, Serena J, Sunaert S, Villringer K, Wouters A, Thijs V, Ebinger M, Endres M, Fiebach JB, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Gerloff C; WAKE-UP Investigators. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med. 2018 Aug 16;379(7):611-622. doi: 10.1056/NEJMoa1804355. Epub 2018 May 16.</citation>
    <PMID>29766770</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>March 21, 2021</last_update_submitted>
  <last_update_submitted_qc>March 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Director of neurology department</investigator_title>
  </responsible_party>
  <keyword>TNK-tPA</keyword>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

